Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02251600 · ClinicalTrials.gov registry record · Phase 1

A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy

A Phase 1 study, sponsored by PTC Therapeutics.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target

NCT02251600 is a Phase 1 study that has completed, run by PTC Therapeutics. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02251600, a Phase 1 study, has completed, sponsored by PTC Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target

Study Summary

Study to characterize the single-state and steady-state dosing of oral deflazacort in pediatric and adolescents subjects.

Interventions

  • DRUG Deflazacort

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2014-12
Est. Completion 2015-10
Phase Phase 1

Sponsor

PTC Therapeutics

52 total trials

What the Registry Record Tells You About NCT02251600

The ClinicalTrials.gov registry entry for NCT02251600 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Deflazacort is the first listed.

NCT02251600 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02251600 about?

NCT02251600 is a clinical study titled "A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy". Study to characterize the single-state and steady-state dosing of oral deflazacort in pediatric and adolescents subjects.

What is the current status of trial NCT02251600?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-12. Estimated completion is 2015-10.

What interventions are being tested in trial NCT02251600?

The interventions under investigation include: Deflazacort (DRUG).

Who is sponsoring clinical trial NCT02251600?

This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.